Lynparza Breast Cancer Clinical Experience Investigation

AstraZeneca

Status: Completed

Conditions: Breast Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT03590938

D0819C00005

Details and patient eligibility

About

To characterise the development of ADRs of bone marrow depression in patients under actual post-marketing use

Full description

To characterise the development of adverse drug reactions (ADRs) of bone marrow depression in patients with unresectable or recurrent BRCA mutated HER2 negative breast cancer who have previously received anticancer chemotherapy under actual post-marketing use.

Enrollment: 111 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Unresectable or recurrent BRCA mutated HER2 negative breast cancer with prior anticancer chemotherapy

Exclusion criteria

• The patients who are not started on Lymparza for the first time